uPAR: a beacon of malignancy?
Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Soluble forms of urokinase plasminogen activator receptor (uPAR) represent a promising new tool in the development of a discriminatory biomarker panel that can influence patient...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2008-09, Vol.14 (18), p.5643-5645 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Soluble forms of urokinase plasminogen activator receptor (uPAR) represent a promising new tool in the development of a discriminatory biomarker panel that can influence patient care. |
|---|---|
| ISSN: | 1078-0432 |
| DOI: | 10.1158/1078-0432.CCR-08-1557 |